Skip to main content
SpringerLink
Log in

Kopfschmerzen

Anwendung monoklonaler Antikörper zur Migräneprophylaxe in der Praxis

  • Zertifizierte Fortbildung Neurologie
  • Published:
InFo Neurologie + Psychiatrie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Ashina M, Lanteri-Minet M, Pozo-Rosich P et al. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2022;21:597-607

  2. Goadsby PJ, Reuter U, Hallström Y et al. A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med. 2017; 377:2123-2132.

  3. Dodick DW, Ashina M, Brandes JL et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia Int J Headache. 2018;38:1026-37

  4. Dodick DW, Silberstein SD, Bigal ME et al. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. JAMA. 2028;319:1999-2008

  5. Stauffer VL, Dodick DW, Zhang Q et al. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial. JAMA Neurol. 2018;75:1080-8

  6. Skljarevski V, Matharu M, Millen BA et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia Int J Headache. 2018;38:1442-54

  7. Tepper S, Ashina M, Reuter U et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16:425-34

  8. Silberstein SD, Dodick DW, Bigal ME et al. Fremanezumab for the Preventive Treatment of Chronic Migraine. N Engl J Med.2017;377:2113-22

  9. Detke HC, Goadsby PJ, Wang S et al. Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. Neurology.2018;91:e2211-e2221

  10. Dodick DW, Lipton RB, Silberstein S et al. Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial. Cephalalgia Int J Headache.2019;39:1075-85

  11. Wang X, Wen D, He Q et al. Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis. J Headache Pain.2022;23:105

  12. Deng H, Li G-G, Nie H et al. Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis. BMC Neurol. 2020;20:57

  13. Soni P, Chawla E. Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: A systematic review and network meta-analysis. Clin Neurol Neurosurg. 2021;209:106893

  14. Reuter U, Goadsby PJ, Lanteri-Minet M et al.Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet Lond Engl.2018;392:2280-7

  15. Ferrari MD, Diener HC, Ning X et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Lond Engl. 2019;394:1030-40

  16. Mulleners WM, Kim B-K, Láinez MJA et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2020;19:814-25

  17. Vandervorst F, Van Deun L, Van Dycke A et al. CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. J Headache Pain. 2021;22:128

  18. Overeem LH, Raffaelli B, Mecklenburg J et al. Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis. CNS Drugs. 2021;35:805-20

  19. Detke HC, Millen BA, Zhang Q et al. Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies. Headache. 2020;60:348-59

  20. Dodick DW, Gottschalk C, Cady R et al. Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing. Headache 2020;60:2220-31

  21. Schwedt T, Reuter U, Tepper S et al. Early onset of efficacy with erenumab in patients with episodic and chronic migraine. J Headache Pain. 2018;19:92

  22. Silberstein SD, Rapoport AM, Loupe PS et al. The Effect of Beginning Treatment With Fremanezumab on Headache and Associated Symptoms in the Randomized Phase 2 Study of High Frequency Episodic Migraine: Post-Hoc Analyses on the First 3 Weeks of Treatment. Headache. 2019;59:383-93

  23. Nichols R, Doty E, Sacco S et al. Analysis of Initial Nonresponders to Galcanezumab in Patients With Episodic or Chronic Migraine: Results From the EVOLVE-1, EVOLVE-2, and REGAIN Randomized, Double-Blind, Placebo-Controlled Studies. Headache. 2019;59:192-204

  24. Tepper SJ, Lucas S, Ashina M et al.Timing and durability of response to erenumab in patients with chronic migraine. Headache. 2021;61:1255-63

  25. Lowe M, Murray L, Tyagi A et al. Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation. J Headache Pain. 2022;23:86

  26. Scheffler A, Schenk H, Wurthmann S et al. CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience. J Headache Pain. 2021;22:111.

  27. Diener H-C, Förderreuther S, Kropp P. Therapie der Migräneattacke und Prophylaxe der Migräne, S1-Leitlinie, 2022, DGN und DMKG

  28. Wang X, Chen Y, Song J, You C. Efficacy and Safety of Monoclonal Antibody Against Calcitonin Gene-Related Peptide or Its Receptor for Migraine: A Systematic Review and Network Meta-analysis. Front Pharmacol. 2021;12:649143

  29. Reuter U, Ehrlich M, Gendolla A et al. Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia Int J Headache. 2022;42:108-18

  30. Mechtler L, Saikali N, McVige J et al. Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine. Front Neurol. 2021;12:788159

  31. Dodick DW, Tepper SJ, Ailani J et al. Risk of hypertension in erenumab-treated patients with migraine: Analyses of clinical trial and postmarketing data. Headache. 2021;61:1411-20

  32. de Vries Lentsch S, van der Arend BWH, Maassen VanDenBrink A, Terwindt GM. Blood Pressure in Patients With Migraine Treated With Monoclonal Anti-CGRP (Receptor) Antibodies: A Prospective Follow-up Study. Neurology. 2022;99:e1897-e1904

  33. Russell FA, King R, Smillie S-J et al. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev. 2014;94:1099-142

  34. Ray JC, Allen P, Bacsi A et al. Inflammatory complications of CGRP monoclonal antibodies: a case series. J Headache Pain. 2021;22:121

  35. Woods RH. Alopecia signals associated with calcitonin gene-related peptide inhibitors in the treatment or prophylaxis of migraine: A pharmacovigilance study. Pharmacotherapy. Pharmacotherapy. 2022;42(10):758-67

  36. Goßrau G, Förderreuther S, Ruscheweyh R et al. [Consensus statement of the migraine and headache societies (DMKG, ÖKSG, and SKG) on the duration of pharmacological migraine prophylaxis]. Nervenarzt. 2022;1-11

  37. Overeem LH, Peikert A, Hofacker MD et al. Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study. Cephalalgia Int J Headache. 2022;42:291-301

  38. Zecca C, Cargnin S, Schankin C et al. Clinic and genetic predictors in response to erenumab. Eur J Neurol. 2022;29:1209-17

  39. Argyriou AA, Dermitzakis EV, Xiromerisiou G, Vikelis M. OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine. Toxins. 2022;14:847

  40. Croop R, Lipton RB, Kudrow D et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet Lond Engl. 2021;397:51-60

  41. Ashina M, Doležil D, Bonner JH et al. A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention. Cephalalgia Int J Headache. 2021;41:33-44

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Neurologie, Campus Großhadern der LMU München, Marchioninistr. 15, 81377, München, Germany

    Ruth Ruscheweyh

  2. Institut für Medizinische Informatik, Biometrie und Epidemiologie (IMIBE), Medizinische Fakultät der Universität Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany

    Hans-Christoph Diener

Authors
  1. Ruth Ruscheweyh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hans-Christoph Diener
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ruth Ruscheweyh.

Ethics declarations

Die Autorin und der Autor erklären, dass sie sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließen. Sie legen folgende potenzielle Interessenkonflikte offen: R. Ruscheweyh erhielt Honorare für Vorträge oder Advisory Boards sowie Unterstützung für Kongressreisen von Hormosan, Novartis, Lilly, Lundbeck, Pharm Allergan und Teva.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags durch zwei unabhängige Gutachten geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ruscheweyh, R., Diener, HC. Anwendung monoklonaler Antikörper zur Migräneprophylaxe in der Praxis. InFo Neurologie 25, 30–39 (2023). https://doi.org/10.1007/s15005-023-3201-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15005-023-3201-3

Search

Navigation